Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30046305 | 1.00 | ALOX5AP (0.31) | ALOX5AP | |
| SCHEMBL12468456 | 0.84 | AGBL2 (0.38) | — | |
| SCHEMBL25283521 | 0.83 | PTGDR2 (0.33) | — | |
| SCHEMBL3703487 | 0.83 | — | — | |
| SCHEMBL16728654 | 0.81 | PLAU (0.34) | — | |
| SCHEMBL29728392 | 0.81 | SSTR4 (0.34) | — | |
| SCHEMBL26970921 | 0.79 | ALDH1A1 (0.36) | ALOX5AP | |
| SCHEMBL30328484 | 0.79 | AGBL2 (0.42) | — | |
| SCHEMBL30507028 | 0.79 | CA1 (0.37) | ALOX5AP | |
| SCHEMBL25316528 | 0.79 | CA1 (0.37) | ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590084-B2 | Oxadiazole HDAC6 inhibitors and uses thereof | EIKONIZO THERAPEUTICS, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-20260055090-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2026-02-26 | — | — | US | disclosed |
| US-12421240-B2 | Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease | HOFFMANN-LA ROCHE INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250250263-A1 | INHIBITING HISTONE DEACETYLASE 6 (HDAC6) | EIKONIZO THERAPEUTICS, INC. (US) | 2025-08-07 | — | — | US | disclosed |
| EP-4504191-A1 | INHIBITING HISTONE DEACETYLASE 6 (HDAC6) | Eikonizo Therapeutics, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| US-20240246937-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-07-25 | — | — | US | disclosed |
| EP-4329889-A1 | IL4I1 INHIBITORS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2024-03-06 | — | — | EP | disclosed |
| WO-2023196605-A1 | INHIBITING HISTONE DEACETYLASE 6 (HDAC6) | EIKONIZO THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20230322747-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322747-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230034723-A1 | HYDROPYRAZINO[1,2-D][1,4]DIAZEPINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2023-02-02 | — | — | US | disclosed |
| WO-2022232333-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2022-11-03 | — | — | WO | disclosed |
| WO-2021084022-A1 | HYDROPYRAZINO[1,2-D][1,4]DIAZEPINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2021-05-06 | — | — | WO | disclosed |
| EP-2490692-B1 | QUINOLINONE-PYRAZOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2016-11-16 | — | — | EP | disclosed |
| US-8895580-B2 | Quinolinone-pyrazolone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2014-11-25 | — | — | US | disclosed |
| WO-2014008223-A2 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-01-09 | — | — | WO | disclosed |
| EP-2490692-A1 | QUINOLINONE-PYRAZOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | Merck Sharp & Dohme Corp. (US) | 2012-08-29 | — | — | EP | disclosed |
| US-20120196845-A1 | QUINOLINONE-PYRAZOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2012-08-02 | — | — | US | disclosed |
| WO-2011049731-A1 | QUINOLINONE-PYRAZOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322747-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | HDAC6, HDAC1, HDAC11 | ALOX5AP 4139/4885 |
| US-12421240-B2 | Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease | HRH3, HRH4, HRH2 | ALOX5AP 2549/4885 |
| US-12590084-B2 | Oxadiazole HDAC6 inhibitors and uses thereof | HDAC6, HDAC1, HDAC9 | ALOX5AP 4748/4885 |
| US-20260055090-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | HDAC6, HDAC1, CTTN | ALOX5AP 4641/4885 |
| US-20120196845-A1 | QUINOLINONE-PYRAZOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, OPRL1, CHRNA5 | ALOX5AP 1199/4885 |
| US-20240246937-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL2 | ALOX5AP 2262/4885 |
| US-20230034723-A1 | HYDROPYRAZINO[1,2-D][1,4]DIAZEPINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HRH3, HRH4, HRH2 | ALOX5AP 2549/4885 |
| US-20250250263-A1 | INHIBITING HISTONE DEACETYLASE 6 (HDAC6) | HDAC6, HDAC1, HDAC9 | ALOX5AP 4436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.